Novartis shows continued commitment in Japan with Lucentis® approval in fourth Japanese indication,

Lucentis is the first anti-VEGF therapy approved for diabetic macular edema (DME) in Japan Pivotal clinical data in Asian patients show a significant increase in mean visual acuity following treatment with Lucentis compared with laser therapy[1] Diabetic

www.novartis.com